Elena Izaga Torralba

Elena Izaga Torralba

Auto-generated profile, based on publicly available information

Elena Izaga Torralba

Cardiology Department, Hospital Puerta del Mar, Cádiz, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AGAlejandro Gutierrez
Alejandro Gutierrez
EIElena Izaga-Torralba
Elena Izaga-Torralba
FCFernando Rivero Crespo
Fernando Rivero Crespo
LGLivia Gheorghe
Livia Gheorghe
DCDolores Cañadas-Pruaño
Dolores Cañadas-Pruaño
FAFernando Alfonso
Fernando Alfonso

21 May 2026 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
BCBernardo Cortese
Bernardo Cortese
GGGabriele Gasparini
Gabriele Gasparini
LMLudovic Meunier
Ludovic Meunier
AGAntonio Gómez-Menchero
Antonio Gómez-Menchero
ESElliot J. Smith
Elliot J. Smith
DJDaniel A. Jones
Daniel A. Jones

1 December 2020 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
EIElena Izaga
Elena Izaga
AGAlejandro Gutiérrez-Barrios
Alejandro Gutiérrez-Barrios
MCManuel Corrales
Manuel Corrales
LGLivia Gheorghe
Livia Gheorghe
GCGermán Calle-Pérez
Germán Calle-Pérez

6 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
JCJorge Chavez
Jorge Chavez
GTGabriela Tirado‐Conte
Gabriela Tirado‐Conte
YKYusuke Kobari
Yusuke Kobari
LALluís Asmarats
Lluís Asmarats
ABAlberto Berenguer
Alberto Berenguer
LNLuis Nombela
Luis Nombela
Background: Most evidence for transcatheter aortic valve replacement (TAVR) for valve‐in‐valve procedures comes from balloon‐expandable and supra‐annular self‐expanding valves. However, data on intra‐annular self‐expanding valves remain limited. The objectives of this registry were to evaluate the short‐ and midterm outcomes of ViV‐TAVR using the intra‐annular self‐expanding valve Navitor platform in a real‐world setting. Methods: The NAViV (Navitor Valve‐in‐Valve) registry is a retrospective, multicenter study that included 200 patients who underwent valve‐in‐valve TAVR with the Portico/Navitor systems. The primary end point was 30‐day device success. Secondary outcomes included intraprocedural technical success, early safety, and all‐cause death and major adverse events at 2 years. Results: The cohort had a high‐risk profile and a high prevalence of small surgical bioprostheses (internal diameter ≤21 mm in 86% of the patients). Technical success was achieved in 96%, with an in‐hospital mortality rate of 2% and early safety at 30 days of 84%. Mean residual gradients after TAVR were low (14 [interquartile range, 10–20] mm Hg), and residual significant aortic regurgitation was rare (1%). Device success was 73.5%, with high residual gradients (≥20 mm Hg) being the main reason for device failure. Two‐year survival and major adverse events were 85.6% and 69.8%, respectively; with low residual gradients and baseline significant AR being independently associated with higher survival. Conclusions: Valve‐in‐valve TAVR using the Portico/Navitor intra‐annular self‐expanding valve demonstrates a favorable procedural safety profile, sustained valve performance, and encouraging midterm survival in intermediate‐ and high‐risk populations. Larger and comparative studies are warranted to confirm these findings.